Funding
← Back to your selection

Pureos Bioventures

pureosbio.com ↗Activity from announced rounds

Activity in this selectionnomura-real-estate-development-co-f095adde

Pureos Bioventures invests in private drug-development companies, with an emphasis on new biological medicines and drug formats.

Venture capital for therapeutic development

Pureos Bioventures backs private companies developing new medicines for serious diseases. Its stated investment focus emphasizes biological drugs and new drug formats. The team combines venture-investment experience with operating, clinical and company-building backgrounds, supporting businesses whose development programs are grounded in scientific research.

Activity recorded by RoundOS

RoundOS records Pureos participation in Tavo Biotherapeutics, NovaGo Therapeutics and AnaCardio. These events span eye disease, central nervous system disorders and heart failure. They show the financings currently covered in this database; the firm’s own website lists a broader portfolio across multiple therapeutic areas.

Sources
Rounds participated in
3
Confirmed lead rounds
1
1 roles undisclosed
New companies
3
First participation on record · 0 follow-on
Funding in participating rounds
$117.5M
3 disclosed · full round size, not this investor’s share

By stage

Series B2
Series A1

By primary sector

Biotech3

By country

Sweden1
Switzerland1
United States1

Rounds

3 in this selection
AnaCardio

AnaCardio develops oral medicines intended to improve heart muscle contraction in people with heart failure.

€62.5MSeries B
Participant
NovaGo Therapeutics

NovaGo Therapeutics is a clinical-stage biotech developing anti-Nogo-A antibodies intended to promote nerve regeneration and functional recovery after central nervous system injury.

CHF 24MSeries B
Lead